臨床婦人科産科78巻9号

2024年09月発行

今月の臨床 ―外来担当医として知っておきたい―婦人科腫瘍の卵巣機能・妊孕性温存療法

子宮体がん編

子宮内膜異型増殖症・早期子宮体がんに対する高用量MPA療法

著者： 三橋暁¹

所属機関： ¹獨協医科大学産科婦人科学教室

ページ範囲：P.783 - P.790

文献概要

●妊孕性温存を希望する若年の子宮内膜異型増殖症および子宮体がん症例に高用量MPA療法が推奨されている．

●若年の子宮内膜異型増殖症および子宮体がん症例は，多囊胞性卵巣症候群や肥満・インスリン抵抗性を有する頻度が高く，高用量MPA療法にメトホルミンを併用することによる再発率の低下が期待される．

●現在，MPAを用いた妊孕性温存療法にメトホルミンを併用する医師主導治験が行われており，その結果が待たれる．

参考文献

1）Rodolakis A, et al：ESGO/ESHRE/ESGE Guidelines for the fertility-sparing treatment of patients with endometrial carcinoma. Hum Reprod Open 2023 : hoac057, 2023

2）National Comprehensive Cancer Network：NCCN Guidelines, Uterine neoplasms, Version 2.2024

3）日本婦人科腫瘍学会（編）：子宮体がん治療ガイドライン2023年版，第5版．金原出版，2023

4）Gallos ID, et al : Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia : a systematic review and metaanalysis. Am J Obstet Gynecol 207 : 266.e1-266.e12, 2012

5）Gunderson CC,et al : Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma : a systematic review. Gynecol Oncol 125 : 477-482, 2012

6）Kaku T, et al : Conservative therapy for adenocarcinoma and atypical endometrial hyperplasia of the endometrium in young women : central pathologic review and treatment outcome. Cancer Lett 167 : 39-48, 2001

7）Niwa K, et al : Outcome of fertility-preserving treatment in young women with endometrial carcinomas. BJOG 112 : 317-320, 2005

8）Ota T, et al : Clinicopathologic study of uterine endometrial carcinoma in young women aged 40 years and younger. Int J Gynecol Cancer 15 : 657-662, 2005

9）Yahata T, et al : Long-term conservative therapy for endometrial adenocarcinoma in young women. Hum Reprod 21 : 1070-1075, 2006

10）Yamazawa K, et al : Fertility-preserving treatment with progestin, and pathological criteria to predict responses, in young women with endometrial cancer. Hum Reprod 22 : 1953-1958, 2007

11）Ushijima K, et al : Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women. J Clin Oncol 25 : 2798-2803, 2007

12）Fujiwara H, et al : Fertility-sparing treatment using medroxyprogesterone acetate for endometrial carcinoma. Oncol Lett 3 : 1002-1006, 2012

13）Ohyagi-Hara C, et al : Efficacies and pregnant outcomes of fertility-sparing treatment with medroxyprogesterone acetate for endometrioid adenocarcinoma and complex atypical hyperplasia : our experience and a review of the literature. Arch Gynecol Obstet 291 : 151-157, 2015

14）Minaguchi T, et al : Combined phospho-Akt and PTEN expressions associated with post-treatment hysterectomy after conservative progestin therapy in complex atypical hyperplasia and stage Ia, G1 adenocarcinoma of the endometrium. Cancer Lett 248 : 112-122, 2007

15）Tamauchi S, et al : Efficacy of medroxyprogesterone acetate treatment and retreatment for atypical endometrial hyperplasia and endometrial cancer. J Obstet Gynaecol Res 44 : 151-156, 2018

16）Yamagami W, et al : Is repeated high-dose medroxyprogesterone acetate（MPA）therapy permissible for patients with early stage endometrial cancer or atypical endometrial hyperplasia who desire preserving fertility? J Gynecol Oncol 29 : e21, 2018

17）Takeda A, et al : Oncologic, fertility, and obstetric outcomes with MPA therapy in women with endometrial cancer and atypical endometrial hyperplasia. J Obstet Gynaecol Res 50 : 633-638, 2024

18）Ushijima K, et al : Trends and characteristics of fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer in Japan : a survey by the Gynecologic Oncology Committee of the Japan Society of Obstetrics and Gynecology. J Gynecol Oncol 34 : e38, 2023

19）Rodolakis A, et al : European Society of Gynecological Oncology Task Force for Fertility Preservation : clinical recommendations for fertility-sparing management in young endometrial cancer patients. Int J Gynecol Cancer 25 : 1258-1265, 2015

20）Evans JM,et al : Metformin and reduced risk of cancer in diabetic patients. BMJ 330 : 1304-1305, 2005

21）Chu D, et al : Effect of metformin use on the risk and prognosis of endometrial cancer : a systematic review and meta-analysis. BMC Cancer 18 : 438, 2018

22）Mitsuhashi A, et al : Phase II study of medroxyprogesterone acetate plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer. Ann Oncol 27 : 262-266, 2016

23）Mitsuhashi A, et al : Long-term outcomes of progestin plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer patients. J Gynecol Oncol 30 : e90, 2019

24）Chae-Kim J, et al : Outcomes of women treated with progestin and metformin for atypical endometrial hyperplasia and early endometrial cancer : a systematic review and meta-analysis. Int J Gynecol Cancer 31 : 1499-1505, 2021

25）Matsuo K,et al : Route-specific association of progestin therapy and concurrent metformin use in obese women with complex atypical hyperplasia. Int J Gynecol Cancer 30 : 1331-1339, 2020

26）Mitsuhashi A, et al : Medroxyprogesterone acetate plus metformin for fertility-sparing treatment of atypical endometrial hyperplasia and endometrial carcinoma : trial protocol for a prospective, randomised, open, blinded-endpoint design, dose-response trial（FELICIA trial）. BMJ Open 10 : e035416, 2020